Beam Therapeutics (NASDAQ:BEAM) Stock Rating Reaffirmed by William Blair
Beam Therapeutics (NASDAQ:BEAM – Get Rating)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued on Wednesday, PriceTargets.com reports. A number of other analysts have also weighed in on BEAM. Cantor Fitzgerald assumed coverage on shares of Beam Therapeutics in a research report on Tuesday, January 31st. They […]